Synovia & Synovia Life Sciences Ltd. (S&S) is a renowned pharmaceutical company headquartered in Mumbai, Maharashtra. Founded in 1975 by Mr.…

Synovia & Synovia Life Sciences Ltd. (S&S) is a renowned pharmaceutical company headquartered in Mumbai, Maharashtra. Founded in 1975 by Mr. Triveni Das, the company has grown steadily over the years into one of the leading pharmaceutical manufacturers, catering to a broad spectrum of healthcare needs through its diverse portfolio of branded and generic medicines. Driven by a strong commitment to quality, innovation, and patient care, S&S has established a significant presence in both domestic and international markets. To support its growing operations, the company operates three state-of-the-art manufacturing facilities located in Mumbai, Pune, and Aurangabad in Maharashtra. In addition, the S&S Group comprises five subsidiaries across India that manufacture Active Pharmaceutical Ingredients (APIs), ensuring a reliable and integrated supply chain for the company's production requirements. This backward integration has enabled the company to maintain consistent product quality, improve operational efficiency, and reduce dependence on external suppliers. Over the years, S&S has successfully expanded its footprint beyond India and now exports its pharmaceutical products to several countries across America, Asia, and Europe. The company's continued focus on research, product development, and regulatory compliance has enabled it to meet stringent international quality standards while strengthening its reputation as a trusted pharmaceutical manufacturer. Guided by its vision of becoming one of the world's most admired pharmaceutical companies and securing a position among the top five pharmaceutical companies globally by 2030, S&S continues to pursue sustainable growth through innovation, operational excellence, and strong corporate values. During F.Y. 2025–26, however, the company's growth trajectory encountered fresh challenges. Owing to evolving geopolitical developments, several countries imposed substantial tariffs on imported pharmaceutical products, adversely affecting S&S's export business and putting pressure on its profit margins. Consequently, the management initiated a comprehensive review of its business strategy with a dual objective of identifying new international markets while simultaneously improving operational efficiency and optimizing manufacturing costs. In this regard, reference may be made to Annexure 1, containing a news article published in Business Trends regarding the company's proposed expansion into newer markets. As part of its strategic response, S&S is evaluating expansion opportunities across various African countries. At the same time, the management recognizes the need to improve operational efficiency at its manufacturing facilities in India to sustain profitability. To assist in these initiatives, the company has engaged the services of MCG, a Dubai-based global consulting firm. Ms. Charlotte Peters has been appointed as the lead consultant to advise the company on its expansion strategy and operational transformation initiatives. One of the first areas identified for review is the inventory management system at S&S's Mumbai manufacturing facility. Since inventory carrying costs have increased significantly in recent years, the management believes that optimizing inventory levels could substantially improve operating efficiency. Accordingly, Charlotte Peters approached Mr. Bipin Patnaik, the Chief Operating Officer (COO), to gain an understanding of the company's existing inventory management practices and evaluate the suitability of introducing a pull-based inventory management system. To facilitate this assessment, Bipin shared a detailed email outlining the various categories of drugs manufactured by the company, their production characteristics, and the specific inventory management requirements associated with each product category. (Refer Annexure 2) At present, S&S follows a push system of inventory management across all its manufacturing facilities, whereby production is undertaken in anticipation of future demand and customer requirements are fulfilled from finished goods inventory. Consequently, finished pharmaceutical products are stored under stringent hygienic conditions until dispatch to customers. To facilitate this, the company leases large warehouse facilities. However, steadily increasing lease rentals have significantly increased inventory holding costs, prompting the management to explore alternative inventory management approaches. As an initial step, Charlotte has requested Bipin to classify the company's products based on four parameters: (i) the ease with which production quantities can be varied to accommodate fluctuations in customer demand, including large bulk orders and smaller orders; (ii) products generating high profit margins where stock-outs could result in significant opportunity losses; (iii) inventory turnover levels; and (iv) the remaining shelf life of medicines from the date of manufacture. Since S&S already has a robust procurement system with its suppliers capable of supporting either push or pull inventory systems, Charlotte has decided to confine her analysis to finished goods at the Mumbai manufacturing facility as a pilot project. While discussing the proposed transition, Mr. Triveni Das expressed the management's expectations regarding the new inventory management system. He expects the proposed system to (i) achieve economies of scale in production and distribution, (ii) guarantee product availability at all times by minimizing stock-outs, (iii) eliminate the need for extensive planning activities such as demand forecasting and resource planning relating to materials, labour, machinery and capital requirements, and (iv) reduce losses arising from drug obsolescence and expiry. Parallel to these operational initiatives, S&S is also dealing with certain regulatory and compliance matters. One such compliance matter relates to payments made to MCG for consultancy services rendered from Dubai. The consulting firm periodically raises invoices denominated in US Dollars, and S&S remits the consideration accordingly. Before processing future remittances, Mr. Mohit Dave, the company's Compliance Officer, seeks advice regarding the maximum amount of foreign exchange that may be remitted for consultancy services without obtaining prior approval from the Reserve Bank of India. Meanwhile, the statutory audit of S&S's consolidated financial statements for F.Y. 2025-26 is also underway. R&K Associates, Chartered Accountants, have been appointed as the statutory auditors. During the year, S&S expanded its international operations by establishing two subsidiaries in various African countries, in addition to its existing five Indian subsidiaries. Consequently, the consolidated financial statements include the financial statements and financial information of seven subsidiaries, all of which have been audited by other auditors. The subsidiaries collectively represent total assets of ₹ 1,010 crores, total revenues of ₹ 1,254 crores, and net cash outflows of ₹ 30 crores. The financial statements of the two overseas subsidiaries have been prepared in accordance with the generally accepted accounting principles applicable in their respective countries and have been audited under the auditing standards prevailing in those jurisdictions. Based on these circumstances, CA. Ravikant Desai, Engagement Partner of R&K Associates, is evaluating the manner in which reference to the work performed by the component auditors should be made, if at all, in the auditor's report on S&S's consolidated financial statements. In addition to operational improvements, S&S is also evaluating strategic investment opportunities that could strengthen its long-term competitive advantage. Several years ago, the company acquired a 15% voting interest in Rediwrap India Limited, a leading manufacturer of pharmaceutical packaging materials and one of S&S's principal suppliers. Owing to this strategic investment, S&S is able to procure nearly 90% of Rediwrap's production for packaging its pharmaceutical products. Historically, Rediwrap has maintained a lead time of approximately five days from receipt of orders, although occasional delays arise when it simultaneously fulfils large orders placed by external customers. Considering the company's proposed shift towards a pull-based inventory management system, Charlotte Peters recommends that S&S acquire Rediwrap India Limited outright. According to her, complete ownership would enable S&S to exercise greater control over the packaging supply chain, improve responsiveness to production requirements, and eliminate the supplier's profit margin through internal transfer pricing arrangements. Although such inter-company profits would stand eliminated upon consolidation, she believes the acquisition would improve operational coordination and enhance overall supply chain efficiency. The senior management, however, remains cautious about the proposal. They are concerned that the acquisition would require substantial capital investment at a time when significant financial resources are already committed towards the company's expansion into African markets. Consequently, the management is apprehensive that pursuing the acquisition may lead to excessive leverage and increase the company's overall financial risk. Annexure 1 Business Trends Synovia & Synovia Life Sciences Ltd. (S&S) Charts Expansion into African Markets Amid Global Trade Challenges Mumbai, 20th February 2026 – Synovia & Synovia Life Sciences Ltd. (S&S), one of India's leading pharmaceutical manufacturers, has announced an ambitious expansion strategy aimed at strengthening its global presence by entering several African markets. The move comes at a time when increasing import tariffs imposed by various countries have adversely affected the company's export business and placed pressure on its profit margins. Recognising the need to diversify its international operations and reduce dependence on traditional export markets, S&S has identified Africa as a key growth destination. With the continent witnessing rising demand for quality healthcare products and several governments implementing investor-friendly economic policies, the company believes that the region offers significant long-term growth opportunities. As part of its expansion strategy, S&S proposes to establish manufacturing facilities in Nigeria, Ethiopia, Egypt, Morocco, South Africa, and Namibia. The initiative is expected to provide the company with better access to regional markets, lower production costs, improved supply chain efficiencies, and enhanced competitiveness in international markets. Since each of these countries has its own legal, regulatory, taxation, and business environment, the company has initiated detailed feasibility studies and regulatory assessments before commencing operations. The company has also begun discussions to acquire existing pharmaceutical businesses in select African countries to accelerate market entry and strengthen its local presence. In certain jurisdictions, investments relating to land acquisition and procurement of manufacturing equipment have already commenced, demonstrating the company's commitment to the expansion programme. According to the management, the African expansion is a key component of S&S's long-term growth strategy and is expected to reduce the adverse impact of global trade barriers while creating new avenues for sustainable growth. The company believes that establishing manufacturing facilities closer to emerging markets will not only improve operational efficiency but also strengthen its ability to respond to changing market dynamics and evolving customer needs. Annexure 2 Bipin Patnaik/ Chief Operating Officer (COO) From: "Bipin Patnaik" Sent: 3rd August 2026 10:00 To: "Charlotte Peters" Cc: Subject: Details of inventory of different products manufactured at the Mumbai facility Attachments: Dear Charlotte, As requested, my team has compiled the inventory-related information for the various categories of products manufactured at our Mumbai facility. The details are provided below for your review. Type 1 Drugs: These are specialty medicines that command high profit margins and contribute approximately 33% of the Mumbai facility's overall profitability. Demand for these products is relatively infrequent; however, they can be manufactured in varying quantities without causing any significant disruption to normal production operations. Owing to their short shelf life, these medicines need to be consumed soon after manufacture. Under the current push-based inventory system, they are produced in anticipation of demand. As actual demand is irregular, a considerable quantity remains unsold in inventory and expires before it can be dispatched, resulting in recurring wastage. These products primarily cater to a niche customer segment. Type 2 Drugs: These consist of common, non-critical medicines with comparatively lower profit margins, contributing around 26% of the Mumbai facility's profitability. They are in consistently high demand throughout the year from wholesalers, hospitals, and large pharmacy chains. Consequently, these products exhibit high inventory turnover, requiring only limited storage time. Customer orders are received through multiple channels, including emails, telephone calls, and annual supply contracts with pre-agreed delivery schedules. Based on these requirements, production managers receive weekly production plans. These medicines have a long shelf life of up to two years from the date of manufacture. Type 3 Drugs: These products account for approximately 40% of the Mumbai facility's profitability and are supplied primarily under long-term contracts with regular customers. Demand for these medicines remains consistently high. However, they are manufactured only in fixed production batches, making it impractical to vary production quantities into smaller or larger lots. Similar to Type 2 products, they have high inventory turnover, require minimal storage space, and possess a relatively long shelf life. Type 4 Drugs: These are low-margin products, contributing approximately 1% of the Mumbai facility's profitability, whose demand is highly volatile and unpredictable. Examples include disaster relief medicines and certain vaccines required during outbreaks of contagious diseases. Manufacturing these products requires significant changes to the production schedule, including substantial setup activities before and after production, thereby interrupting normal manufacturing operations. In addition, these medicines have a very short shelf life, requiring rapid consumption after production. Owing to the uncertainty of demand, the company frequently incurs losses arising from expired inventory in this product category. I hope the above information will be useful for your assessment of the suitability of introducing a pull-based inventory management system at our Mumbai facility. Please let me know if you require any additional information or clarification. Regards, Bipin Bipin Patnaik Chief Operating Officer (COO)